Actively Recruiting
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
Led by Baylor College of Medicine · Updated on 2025-07-20
200
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.
CONDITIONS
Official Title
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child is between 7 and 17 years old at enrollment
- Primary diagnosis of OCD for more than 6 months with a CY-BOCS score of 16 or higher
- Child has been on stable and maximally tolerated SRI medication (excluding paroxetine) for at least 12 weeks
- Both child and parent speak English
- Both child and parent live in Texas
You will not qualify if you...
- Diagnosis of bipolar disorder, psychotic disorder, or intellectual disability
- Severe current suicidal or homicidal thoughts or self-injury requiring medical intervention
- Receiving concurrent psychotherapy for OCD
- Started psychotropic medication less than 4 weeks before enrollment or stimulant/psychoactive medication less than 2 weeks before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Baylor College of Medicine
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
E
Eric A Storch, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here